Processa Pharmaceuticals Files S-1

TL;DR

Processa Pharma just filed an S-1, looks like they're gearing up for a public offering.

AI Summary

Processa Pharmaceuticals, Inc. filed an S-1 registration statement on December 20, 2024, for an unspecified offering. The company, formerly Heatwurx, Inc., is incorporated in Delaware and headquartered in Hanover, Maryland. This filing indicates a step towards a public offering or significant corporate action.

Why It Matters

This S-1 filing is a crucial step for Processa Pharmaceuticals, signaling their intent to raise capital through a public offering, which could fund their drug development pipeline.

Risk Assessment

Risk Level: medium — S-1 filings are typically associated with new public offerings or significant corporate events, which inherently carry market and execution risks.

Key Numbers

• 333-283986 — SEC File Number (Identifies the specific registration statement)
• 20241220 — Filing Date (Date the S-1 was submitted to the SEC)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — Registrant
• Heatwurx, Inc. (company) — Former company name
• George Ng (person) — Chief Executive Officer
• Foley & Lardner LLP (company) — Legal counsel
• 333-283986 (dollar_amount) — SEC File Number
• 20241220 (dollar_amount) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — of common stock at an exercise price of $0.0001 per share of common stock. The public o
• $ — ees and expenses in the amount of up to $, and for its clearing expenses in the a

Filing Documents

• forms-1.htm (S-1) — 514KB
• forms-1_001.jpg (GRAPHIC) — 17KB
• forms-1_002.jpg (GRAPHIC) — 104KB
• ex23-1.htm (EX-23.1) — 5KB
• ex107.htm (EX-FILING FEES) — 33KB
• 0001493152-24-051075.txt ( ) — 720KB

Risk Factors

Risk Factors 9 Special Note Regarding Forward-Looking Statements 13

Use of Proceeds

Use of Proceeds 14 Dividend Policy 15 Capitalization 15

Description of Capital Stock

Description of Capital Stock 17

Description of Securities We Are Offering

Description of Securities We Are Offering 20 Material U.S. Federal Income Tax Consequences 22 Plan of Distribution 28 Legal Matters 30 Experts 30 Incorporation of Certain Information by Reference 30 Where You Can Find More Information 31 i ABOUT THIS PROSPECTUS You should rely only on the information we have provided or incorporated by reference into this prospectus, any applicable prospectus supplement and any related free writing prospectus. We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information By Reference,” before deciding to invest in our securities. We have not, and the placement agent and its affiliates have not, authorized anyone to provide you with any information or to make any representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. We do not, and the placement agent and its affiliates do not, take any responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you. This prospectus is not an offer to sell or an offer to buy securities in any jurisdiction where offers and sales are not permitted. The information in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of securities. You should also read and consider the information in the documents to which we have referred you under the caption “Where You Can Find More Information” in the prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference fi

View Full Filing

View this S-1 filing on SEC EDGAR